



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
)
Stevan D. Tofovic, et al.)
) Group Art Unit: 1614
Serial No.: 10/633,410)
) Examiner:
Filed: August 4, 2003)
)
For: AMINISTRATION OF ESTRADIOL)
)
METABOLITES FOR INHIBITION OF)
)
DRUG-INDUCED NEPHROTOXICITY)
)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

In compliance with the duty of disclosure as defined in 37 C.F.R. § 1.56 enclosed herewith for the Examiner's consideration is a copy of the publications listed on the attached Form PTO-1449. This statement is made pursuant to 37 C.F.R. § 1.97(b) since a first Office Action on the merits has not been mailed in the above-identified application.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that:
(1) additional information material to the examination of this application does not exist; (2) the information, protocols, results and the like reported by third parties are accurate or

enabling; or (3) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By 
Mary-Elizabeth Buckles
Registration No. 31,907

REED SMITH LLP
Attorneys for Applicant

Mary-Elizabeth Buckles
1301 K Street, N.W.
Suite 1100-East Tower
Washington, D.C. 20005
(202) 414-9267

Filed: January 15, 2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)
(37 CFR 1.96(b))

ATTY. DOCKET NO.

SERIAL NO.
10/633,410

APPLICANT

Stevan D. Tofovic, et al.

FILING DATE

August 4, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	TAB	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC ACTION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATIO N YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

1	Lindner, A. B., et al., <u>N. Engl. J. Med.</u> 290:697 (1974)
2	United States Renal Data System:1993 Annual Data Report, MD. U.S. Department of Health and Human Services, Public Health Services, National Institutes of Health, p. xvi (1993)
3	Neugarten, J., et al., <u>J. Am. Soc. Nephrol.</u> 11:319 (2000)
4	Silbiger, S. R., et al., <u>Am. J. Kid. Disease</u> 25:515 (1995)
5	Manson, J. E., et al., <u>N. Engl. J. Med.</u> 345: 34 (2001)
6	Braunstein, G. D., <u>New England J. Med.</u> 328:490 (1993)
7	Ball, P., et al., <u>Am. J. Obstet. & Gyn.</u> 163: 2163 (1990)
8	Lowry, O. H., et al., <u>J. Biol. Chem.</u> 193: 265 (1951)
9	Grond, J., et al., <u>Contributions to Nephrology</u> 60:83 (1988)
10	Reckelhoff, J.F., et al., <u>Clin. & Exp. Pharm. & Phys.</u> 26:127 (1999)

EXAMINER: Initial citati n c nsid r d. Draw line thr ough citati n if n t in c nf rmance and n t considered.
Include copy of this form with next communication to applicant.

Pag 1 of 1